Dizal’s Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations

Sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, is the first Chinese Innovative drug approved for NSCLC Patients with EGFR Exon20ins Approval based on the results of primary endpoint from WU-KONG6 study, which demonstrated a superior confirmed objective…